CU24534B1 - Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 - Google Patents

Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Info

Publication number
CU24534B1
CU24534B1 CU2017000137A CU20170137A CU24534B1 CU 24534 B1 CU24534 B1 CU 24534B1 CU 2017000137 A CU2017000137 A CU 2017000137A CU 20170137 A CU20170137 A CU 20170137A CU 24534 B1 CU24534 B1 CU 24534B1
Authority
CU
Cuba
Prior art keywords
ganglioside
nano
synthetic
ceramide
stimulated
Prior art date
Application number
CU2017000137A
Other languages
English (en)
Other versions
CU20170137A7 (es
Inventor
Báez Gretchen Bergado
García Lisset Chao
Rodríguez Mabel Cruz
Gómez Audry Fernández
Molina Luis Fernández
Suárez Narjara González
Fernández Diana Rosa Hernández
BARRANCO Jesús Arturo JUNCO
López Miguel Antonio López
Vargas Ángel Alexis Manso
Pardillo Circe Mesa
Martínez Dayana Pérez
Ramírez Belinda Sánchez
Murguía Blanca Idelmis Tolón
Bencomo Vicente Guillermo Verez
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2017000137A priority Critical patent/CU24534B1/es
Priority to EP18822259.0A priority patent/EP3711775A1/en
Priority to KR1020207016172A priority patent/KR20200086315A/ko
Priority to MX2020004644A priority patent/MX2020004644A/es
Priority to JP2020525926A priority patent/JP7332592B2/ja
Priority to PCT/CU2018/050003 priority patent/WO2019086056A1/es
Priority to AU2018359358A priority patent/AU2018359358B2/en
Priority to CA3079105A priority patent/CA3079105A1/en
Priority to BR112020008668-1A priority patent/BR112020008668A2/pt
Priority to EA202091116A priority patent/EA202091116A1/ru
Priority to NZ764565A priority patent/NZ764565A/en
Priority to US16/760,954 priority patent/US11806396B2/en
Priority to SG11202004180SA priority patent/SG11202004180SA/en
Priority to CN201880071890.1A priority patent/CN111295200A/zh
Priority to TW107137740A priority patent/TWI719351B/zh
Priority to ARP180103229A priority patent/AR114139A1/es
Publication of CU20170137A7 publication Critical patent/CU20170137A7/es
Priority to CONC2020/0006548A priority patent/CO2020006548A2/es
Priority to ZA2020/03218A priority patent/ZA202003218B/en
Publication of CU24534B1 publication Critical patent/CU24534B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001144—Hormones, e.g. calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Abstract

<p>Esta invención describe adyuvantes nano-particulados basados en diferentes variantes sintéticas del gangliósido GM3. Cuando el ácido graso presente en el ceramido del GM3 sintético es el ácido esteárico GM3 (18:0) se estimula una respuesta inmune específica de tipo humoral. En el caso de que sea el ácido oleico GM3 (18:1) el que se encuentre en el ceramido del GM3, la respuesta inmune específica que se estimula es de tipo celular. Particularmente, esta invención provee composiciones vacunales inmunogénicas que tienen como antígenos los receptores de factores de crecimiento HER1, HER2, HER3 solos o combinados o el péptido GnRHm1-TT y como adyuvantes nano-partículas formadas mediante la asociación del gangliósido GM3 formado por ácidos grasos totalmente sintéticos a proteínas hidrofóbicas del complejo de membrana externa de Ia bacteria Neisseria meningitidis.</p>
CU2017000137A 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 CU24534B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CU2017000137A CU24534B1 (es) 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
EA202091116A EA202091116A1 (ru) 2017-11-06 2018-10-24 Наночастицы, содержащие синтетические варианты ганглиозида gm3, в качестве адъювантов в вакцинах
NZ764565A NZ764565A (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
MX2020004644A MX2020004644A (es) 2017-11-06 2018-10-24 Nano-particulas que contienen variantes sinteticas del gangliosido gm3 como adyuvantes en vacunas.
JP2020525926A JP7332592B2 (ja) 2017-11-06 2018-10-24 ワクチンアジュバントとしての、ｇｍ３ガングリオシドの合成バリアントを含有するナノ粒子
PCT/CU2018/050003 WO2019086056A1 (es) 2017-11-06 2018-10-24 Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas
AU2018359358A AU2018359358B2 (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
CA3079105A CA3079105A1 (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
BR112020008668-1A BR112020008668A2 (pt) 2017-11-06 2018-10-24 nanopartículas que contêm variantes sintéticas de gangliosídeo gm3 como adjuvantes em vacinas
EP18822259.0A EP3711775A1 (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
KR1020207016172A KR20200086315A (ko) 2017-11-06 2018-10-24 백신 보조제로서 gm3 강글리오시드의 합성 변이체를 포함하는 나노입자
US16/760,954 US11806396B2 (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
SG11202004180SA SG11202004180SA (en) 2017-11-06 2018-10-24 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines
CN201880071890.1A CN111295200A (zh) 2017-11-06 2018-10-24 作为疫苗中的佐剂的包含合成的神经节苷脂gm3变体的纳米颗粒
TW107137740A TWI719351B (zh) 2017-11-06 2018-10-25 於疫苗中作為佐劑的包含ｇｍ３神經節苷脂的合成變體之奈米粒子
ARP180103229A AR114139A1 (es) 2017-11-06 2018-11-06 Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas
CONC2020/0006548A CO2020006548A2 (es) 2017-11-06 2020-05-28 Nano-partículas que contienen variantes sintéticas del gangliósido gm3 como adyuvantes en vacunas
ZA2020/03218A ZA202003218B (en) 2017-11-06 2020-05-29 Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2017000137A CU24534B1 (es) 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Publications (2)

Publication Number Publication Date
CU20170137A7 CU20170137A7 (es) 2019-06-04
CU24534B1 true CU24534B1 (es) 2021-07-02

Family

ID=64745822

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000137A CU24534B1 (es) 2017-11-06 2017-11-06 Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Country Status (18)

Country Link
US (1) US11806396B2 (es)
EP (1) EP3711775A1 (es)
JP (1) JP7332592B2 (es)
KR (1) KR20200086315A (es)
CN (1) CN111295200A (es)
AR (1) AR114139A1 (es)
AU (1) AU2018359358B2 (es)
BR (1) BR112020008668A2 (es)
CA (1) CA3079105A1 (es)
CO (1) CO2020006548A2 (es)
CU (1) CU24534B1 (es)
EA (1) EA202091116A1 (es)
MX (1) MX2020004644A (es)
NZ (1) NZ764565A (es)
SG (1) SG11202004180SA (es)
TW (1) TWI719351B (es)
WO (1) WO2019086056A1 (es)
ZA (1) ZA202003218B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CU24637B1 (es) 2019-12-24 2022-12-12 Ct Ingenieria Genetica Biotecnologia Polipéptidos que comprenden mutantes del vegf-a humano con re-arreglos de puentes disulfuro y composiciones que los contienen
CU20200075A7 (es) 2020-10-22 2022-05-11 Ct Ingenieria Genetica Biotecnologia Antígeno quimérico que comprende el dominio extracelular de pd-l1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
PE20020572A1 (es) * 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
US7776346B2 (en) 2003-05-22 2010-08-17 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Personal product compositions comprising structured benefit agent premix or delivery vehicle
CU23739A1 (es) 2008-09-30 2011-12-28 Ct Ingenieria Genetica Biotech Composición farmacéutica utilizando combinaciones de variantes de la hormona liberadora de las gonadotropinas (gnrh) como inmunógeno
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CU24299B1 (es) * 2013-08-02 2017-12-08 Centro De Inmunología Molecular Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Also Published As

Publication number Publication date
AU2018359358B2 (en) 2022-08-04
AU2018359358A1 (en) 2020-06-11
EA202091116A1 (ru) 2020-09-24
SG11202004180SA (en) 2020-06-29
NZ764565A (en) 2024-02-23
CA3079105A1 (en) 2019-05-09
JP2021501792A (ja) 2021-01-21
JP7332592B2 (ja) 2023-08-23
CU20170137A7 (es) 2019-06-04
KR20200086315A (ko) 2020-07-16
WO2019086056A1 (es) 2019-05-09
EP3711775A1 (en) 2020-09-23
US11806396B2 (en) 2023-11-07
CO2020006548A2 (es) 2020-08-21
TW201927804A (zh) 2019-07-16
MX2020004644A (es) 2020-07-24
TWI719351B (zh) 2021-02-21
BR112020008668A2 (pt) 2020-10-06
ZA202003218B (en) 2022-05-25
CN111295200A (zh) 2020-06-16
AR114139A1 (es) 2020-07-29
US20200268878A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
CU24534B1 (es) Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
EP3556353A3 (en) Lipid nanoparticle vaccine adjuvants and antigen delivery systems
MX363529B (es) Vesículas de membrana externa.
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
EA201691146A1 (ru) Иммуногенное соединение
BR112015012711A2 (pt) método de produção de uma vacina de mycoplasma
MX346094B (es) Método de administración de vacunas.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
AR059647A1 (es) Antigenos vacunales quimericos contra el virus de la influenza aviar
AR099960A1 (es) Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
EA201692375A1 (ru) Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
BR112014026407A2 (pt) formulação de vacina líquida
CU20100144A7 (es) Composiciones vacunales a base de sticholisina encapsulada en liposomas
CU24299B1 (es) Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
PL404229A1 (pl) Wyizolowany immunogenny antygen bakteryjny i jego zastosowanie w profilaktyce i leczeniu zakażeń wywołanych przez Gram-ujemne bakterie
BR112014001287A2 (pt) vacina recombinante do vírus da leucemia felina contendo gene otimizado do envelope do vírus da leucemia felina
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
MA40034A (fr) Fabrication et utilisation d&#39;ovotransferrine moderne (otf-m)
BR112015011944A2 (pt) preparação de vacinas vivas